Allosteric MEK1/2 inhibitor Refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

Neoplasia (United States)

Volumn 15, Issue 10, 2013, Pages 1161-1171

  Schmieder, Roberta ^a   Puehler, Florian ^a   Neuhaus, Roland ^a   Kissel, Maria ^a   Adjei, Alex A ^b   Miner, Jeffrey N ^c   Mumberg, Dominik ^a   Ziegelbauer, Karl ^a   Scholz, Arne ^a  

^a BAYER PHARMA AG   (Germany)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Ardea Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 86 9766; MITOGEN ACTIVATED PROTEIN KINASE KINASE; REFAMETINIB; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG;

ALLOGRAFT; ALPHA FETOPROTEIN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

ALLOGRAFTS; ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIPHENYLAMINE; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NIACINAMIDE; PHENYLUREA COMPOUNDS; RATS; SULFONAMIDES;

EID: 84887093344     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13812     Document Type: Article

References (38)

1. Venook AP, Papandreou C, Furuse J, and de Guevara LL (2010). The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15(suppl 4), 5-13.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
3. Ma YT and Palmer DH (2012). Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 12, 465-473.
4. Olsen SK, Brown RS, and Siegel AB (2010). Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 3, 55-66.
5. Roberts PJ and Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310.
6. Friday BB and Adjei AA (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14, 342-346.
7. Fremin C and Meloche S (2010). From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3, 8.
8. Wong CM and Ng IO (2008). Molecular pathogenesis of hepatocellular carcinoma. Liver Int 28, 160-174.
9. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, and Wittekind C (2003). Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712.
10. Nonomura A, Ohta G, Hayashi M, Izumi R, Watanabe K, Takayanagi N, Mizukami Y, and Matsubara F (1987). Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 82, 512-518.
11. Jagirdar J, Nonomura A, Patil J, Thor A, and Paronetto F (1989). ras oncogene p21 expression in hepatocellular carcinoma. J Exp Pathol 4, 37-46.
12. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, and Bosserhoff AK (2006). Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 16, 451-456.
13. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1997). Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236, 54-58.
14. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto M, and Aoyagi Y (2004). Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24, 432-436.
15. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, et al. (1998). Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27, 951-958.
16. Lupberger J and Hildt E (2007). Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13, 74-81.
17. Nagy LE (2004). Molecular aspects of alcohol metabolism: transcription factors involved in early ethanol-induced liver injury. Annu Rev Nutr 24, 55-78.
18. Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, et al. (2009). Ethanol-TGFα-MEK signaling promotes growth of human hepatocellular carcinoma. J Surg Res 154, 187-195.
19. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, and Baba HA (2008). Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48, 83-90.
20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109.
21. Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, et al. (2006). Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5, 657-664.
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
23. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. (2009). Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10, 25-34.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology/Hepatobiliary Cancers v.2004. Available at: http://www.nccn.org/.
25. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, et al. (2009). RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 69, 6839-6847.
26. Jonkers J and Berns A (2002). Conditional mouse models of sporadic cancer. Nat Rev Cancer 2, 251-265.
27. Killion JJ, Radinsky R, and Fidler IJ (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17, 279-284.
28. Mohandas K (2004). Hepatitis B associated hepatocellular carcinoma: epidemiology, diagnosis and treatment. Hep B Annual 1, 140-152.
29. Chou TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
30. Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, et al. (2013). Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res 73, 4050-4060.
31. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, and Sebolt-Leopold J (2005). A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7, 336-347.
32. Huynh H, Soo KC, Chow PK, and Tran E (2007). Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6, 138-146.
33. Poulikakos PI, Zhang C, Bollag G, Shokat KM, and Rosen N (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 18, 427-430.
34. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, et al. (2013). RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 13, 594-602.
35. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, and Smalley KS (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102, 1724-1730.
36. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, et al. (2011). Phase II study of the mitogenactivated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 29, 2350-2356.
37. U.S. National Institutes of Health. Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer (BASIL), 2010. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01204177?term=NCT01204177&rank=1. Accessed October 01, 2013.
38. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, et al. (2013). Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res 19, 1232-1243.